BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Infographics: Dynamic digital data analysis
BioWorld 2024 review
BioWorld MedTech 2024 review
BioWorld Science 2024 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Israel
Rise of obesity
Radiopharmaceuticals
Biosimilars
Aging
IVDs on the rise
Coronavirus
Artificial intelligence
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Sunday, January 12, 2025
See today's BioWorld
Home
» Australia's Aravax to advance peptide-immunotherapy effort in phase II peanut allergy trial
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Australia's Aravax to advance peptide-immunotherapy effort in phase II peanut allergy trial
Sep. 25, 2019
By
Tamra Sami
No Comments
PERTH, Australia – Melbourne-based Aravax Pty Ltd. is progressing its peanut allergy immunotherapy to phase II trials after reporting positive phase I data for lead candidate PVX-108.
BioWorld
